1910 Genetics seals $22m Series A

1910 Genetics, a biotechnology company integrating artificial intelligence, computation and biological automation to improve drug development, has secured $22 million in Series A funding.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this